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Background
We aimed to perform microbiological analysis of Gram
positive infections in patients infected with HIV (PIH).
Methods
We performed a retrospective and compared study,
between 01 January 2007 – 31 December 2010, in the
Infectious Diseases Hospital of Craiova, on two groups of
adults patients (Px): group A - 114 PIH and group B -
1442 Px non HIV, which had been diagnosed with non-
tuberculosis bacterial infections (BI) with established etiol-
ogy. For each group we analyzed the incidence, clinical
spectrum, etiology and antibiotic susceptibility phenotype
of Gram positive infections (GPI). For the statistical analy-
sis we used the Fischer test; threshold values are statisti-
cally significant for p<0.05 and relative risk (RR) >2.
Results
Incidence: group A vs. group B: BI-114 PIH (22.66%) vs.
1442 Px (8.7%) (p=0.000, RR=17.23), GPI-59 (51.75%)
vs. 378 (26.21%) (p<0.0001); S aureus – 31 PIH (27.19%)
vs. 58 Px (4.92%) (p=0.000; RR=6.42), S pneumoniae – 24
PIH (21.05%) vs. 234 Px (16.22%) (p=0.01; RR=2.79),
Enterococcus spp. – 2 PIH (1.75%) vs. 7 Px (0.49%)
(p<0.05), S pyogenes – 2 PIH (1.75%) vs. 77 Px (5.33%)
(p<0.05) and S viridans – 2 Px (0.14%) only in group B.
The clinical spectrum was dominated by lower respiratory
tract infections: 29 PIH (49.15%) vs. 237 Px (69.09%)
(p=0.004). Sensitivity to antibiotics: S pneumoniae, group
A vs. group B: teicoplanin, linezolid 24 (100%) vs. 234
(100%) (p<0.05), moxifloxacin, 24 (100%) vs. 228 (97.43%)
(p<0.05), vancomycin 24 (100%) vs. 228 (97.43%) (p<0.05),
erythromycin -18 (75%) vs. 166 (70.94%) (p<0.05),
co-trimoxazole 9 (37.5%) vs. 119 (50.84%) (p<0.05), peni-
cillin 10 (41.62%) vs. 92 (39.31%) (p <0.05), ceftriaxone,
21 (87.5%) vs. 198 (84.61%) (p <0.05), rifampicin 18 (75%)
vs. 217 (92.73%) (p=0.000) antibiotic sensitivity of S aur-
eus, group A vs. group B (41 strains tested): oxacillin
24 (77.41%) vs. 33 (80.48%) (p>0.05) erythromycin,
13 (41.93%) vs. 21 (51.21%) (p<0.05), co-trimoxazole
8 (25.80%) vs. 29 (70.73%) (p<0.05), amikacin 29 (93.54%)
vs. 38 (92.68%) (p<0.05), vancomycin 31 (100%) vs.
39 (95.12%) (p<0.05), linezolid 31 (100%) vs. 41 (100%),
clindamycin 29 (93.54%) vs. 38 (92.68%) (p<0.05).
Conclusion
Gram positive infections are more common in PIH versus
Px non-HIV; the clinical spectrum is dominated by acute
respiratory tract infections, regardless of HIV status. HIV
infection was associated with high risk of resistance of S
pneumoniae to co-trimoxazole, rifampicin and of S aureus
to co-trimoxazole.
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